Abbott Laboratories cash flow to debt ratio of 63.49% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

Abbott Laboratories's free cash flow has increased 16.44% from $6.35G last year to $7.39G, signaling increasing performance

Abbott Laboratories's debt to equity ratio is 0.64, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

Abbott Laboratories's debt has increased relative to shareholder equity from 0.32 last year to 0.64 today, signaling weakened financials

Abbott Laboratories has a net debt to EBITDA ratio of 0.57x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Abbott Laboratories's interest coverage ratio of 12.45 indicates that earnings with good margin can cover interest payments on company debt

Abbott Laboratories's profit margin has decreased (-63.55%) in the last year from 31.95% to 11.65%, signaling decreasing performance

Abbott Laboratories's short-term assets of $26.00G exceed its short-term liabilities of $16.50G

Abbott Laboratories's return on assets of 4.97% is lower than the 5.00% threshold, indicating inefficient asset utilization

Abbott Laboratories's return on equity of 10.52%, is lower than 15.00%, indicating bad performance

Abbott Laboratories's operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Abbott Laboratories had positive net income in 5.00 out of 5 years, indicating stable and consistent earnings

Abbott Laboratories has positive free cash flow, indicating the company generates cash after capital expenditures

Abbott Laboratories has a free cash flow yield of 3.84%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Abbott Laboratories's yearly earnings has decreased -51.32% since last year from $13.40G to $6.52G, signaling decreasing performance

Abbott Laboratories's yearly revenue has increased 5.67% since last year from $41.95G to $44.33G, signaling increasing performance

ROIC 6.07% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.

Abbott Laboratories's 3-year revenue CAGR of 0.51% is positive, indicating growing revenue over the past 3 years

Abbott Laboratories had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance

Abbott Laboratories had positive ROE in 5.00 out of 5 years, indicating consistent and reliable returns on equity

Abbott Laboratories is overvalued relative to its fair value price of 58.44 based on Discounted Cash Flow model

Abbott Laboratories has an earnings yield of 2.80%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Abbott Laboratories is overvalued relative to its fair value price of 42.78 based on EBITDA multiple model

Abbott Laboratories has an EV/EBITDA ratio of 17.23x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Abbott Laboratories is overvalued relative to its fair value price of 73.35 based on Earnings Fair Value model

Abbott Laboratories has no meaningful EPS growth rate; PEG ratio cannot be computed.

Abbott Laboratories has a price-to-book ratio of 3.75x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Abbott Laboratories has a price-to-sales ratio of 4.16x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue